DCGI Approved DRDO’s Anti-Covid Oral Drug To Roll Out By May 11

0
290

An Anti-COVID-19 therapeutic application of the drug 2-Deoxy-D-Glucose (2-DG) has been developed by INMAS, a lab of DRDO, in collaboration with Dr Reddy’s Laboratories, Hyderabad. The drug will help in faster recovery of Covid-19 patients.

The drug comes in powder form in sachet, which is taken orally by dissolving it in water.


The Drugs Controller General of India (DCGI) has granted permission for emergency use of anti-COVID-19 therapeutic application of the drug 2-Deoxy-D-Glucose (2-DG) developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy’s Laboratories (DRL),Hyderabad.

DRDO chief G. Satheesh Reddy on Sunday said the anti-COVID drug, which has been approved for emergency use, will be rolled out by May 11.

Explaining further, the DRDO chief said the drug will help neutralise most of the COVID-19 symptoms and will prevent the growth of the virus inside the body. Regarding the availability of the drug, Reddy said arrangements for proper distribution across all hospitals need to be done and a team is already working on the same.

In a release issued on Saturday, the Ministry of Defence said that as per the order, emergency use of this drug as adjunct therapy in moderate to severe COVID-19 patients is permitted. It added that being a generic molecule and analogue of glucose, it can be easily produced and made available in plenty in the country.

The drug comes in powder form in sachet, which is taken orally by dissolving it in water. It accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production. Its selective accumulation in virally infected cells makes this drug unique.

Clinical trial results have shown that this molecule helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence, noted the release.

An anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by INMAS, a lab of DRDO, in collaboration with Dr Reddy’s Laboratories, Hyderabad. The drug will help in faster recovery of Covid-19 patients.

It further said that higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in COVID-19 patients.